Literature DB >> 24315013

Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients.

Kristina Blaslov1, Karin Zibar2, Tomislav Bulum2, Lea Duvnjak2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24315013     DOI: 10.1016/j.clinre.2013.10.013

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


× No keyword cloud information.
  5 in total

Review 1.  Translational approaches: from fatty liver to non-alcoholic steatohepatitis.

Authors:  Natalia Rosso; Norberto C Chavez-Tapia; Claudio Tiribelli; Stefano Bellentani
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 2.  Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH.

Authors:  Gianluca Svegliati-Baroni; Bárbara Patrício; Gessica Lioci; Maria Paula Macedo; Amalia Gastaldelli
Journal:  Int J Mol Sci       Date:  2020-08-13       Impact factor: 5.923

Review 3.  Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD.

Authors:  Marta Seghieri; Alexander S Christensen; Andreas Andersen; Anna Solini; Filip K Knop; Tina Vilsbøll
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-06       Impact factor: 5.555

Review 4.  Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update.

Authors:  Areti Sofogianni; Athanasios Filippidis; Lampros Chrysavgis; Konstantinos Tziomalos; Evangelos Cholongitas
Journal:  World J Hepatol       Date:  2020-08-27

5.  Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Authors:  Yuan Zhu; Jiao Xu; Dong Zhang; Xingyu Mu; Yi Shi; Shangtao Chen; Zengxiang Wu; Shuangqing Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-09       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.